Nanocrystals for the parenteral delivery of poorly water-soluble drugs
Source abstract
Abstract
Nanocrystals have drawn increasing interest in pharmaceutical industry because of the ability to improve dissolution of poorly water-soluble drugs. Nanocrystals can be produced by top-down and bottom-up technologies and have been explored for a variety of therapeutic applications. Here we review the methods of nanocrystal production and parenteral applications of nanocrystals. We also discuss remaining challenges in the development of nanocrystal products.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (96)
Show source-provided references
1. Drug nanoparticles: formulating poorly water-soluble compounds10.1177/0192623307310946 ↗
2. Nanosuspensions in drug delivery10.1038/nrd1494 ↗
3. Solid dispersions: revival with greater possibilities and applications in oral drug delivery
4. A cremophor-free self-microemulsified delivery system for intravenous injection of teniposide: evaluation in vitro and in vivo10.1208/s12249-012-9809-0 ↗
5. Paclitaxel/β-cyclodextrin complexes for hyperthermic peritoneal perfusion – formulation and stability10.1016/j.ejpb.2006.11.025 ↗
6. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery
7. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain10.1016/j.jconrel.2010.06.018 ↗
8. An excellent delivery system for improving the oral bioavailability of natural vitamin E in rats10.1208/s12249-012-9819-y ↗
9. Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies10.3109/02652048.2011.590612 ↗
10. Beyond the imaging: limitations of cellular uptake study in the evaluation of nanoparticles10.1016/j.jconrel.2012.04.042 ↗
11. Nanosuspensions: a promising drug delivery strategy10.1211/0022357023691 ↗
12. Nanonization of itraconazole by high pressure homogenization: Stabilizer optimization and effect of particle size on oral absorption10.1002/jps.22587 ↗
13. Lutein nanocrystals as antioxidant formulation for oral and dermal delivery10.1016/j.ijpharm.2011.08.026 ↗
14. Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal10.1016/j.ijpharm.2011.08.023 ↗
15. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery10.1016/j.ijpharm.2008.09.022 ↗
16. Preparation and antitumor study of camptothecin nanocrystals10.1016/j.ijpharm.2011.05.075 ↗
17. Development of a nanocrystalline paclitaxel formulation for Hipec treatment10.1007/s11095-012-0765-x ↗
18. State of the art of nanocrystals – special features, production, nanotoxicology aspects and intracellular delivery10.1016/j.ejpb.2011.01.007 ↗
19. Doxil®—the first FDA-approved nano-drug: lessons learned10.1016/j.jconrel.2012.03.020 ↗
20. Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS10.1016/j.biopha.2010.10.003 ↗
21. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review10.1586/ecp.11.7 ↗
22. Production methods for nanodrug particles using the bottom-up approach10.1016/j.addr.2011.03.011 ↗
23. Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth10.1021/la700811b ↗
24. In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations10.1016/j.ijpharm.2012.02.004 ↗
25. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives10.1016/j.ijpharm.2010.07.044 ↗
26. Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying10.1016/j.ijpharm.2010.10.055 ↗
27. Preparation of drug nanocrystals by controlled crystallization: application of a 3-way nozzle to prevent premature crystallization for large scale production10.1016/j.ejps.2009.07.005 ↗
28. A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying10.1016/j.jconrel.2008.03.002 ↗
29. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology10.1016/j.addr.2010.12.007 ↗
30. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation10.1016/j.ejpb.2005.05.009 ↗
31. Nanosizing: a formulation approach for poorly-water-soluble compounds
32. Generation of wear during the production of drug nanosuspensions by wet media milling10.1016/j.ejpb.2012.01.005 ↗
33. The effect of mechanical processing on surface stability of pharmaceutical powders: visualization by atomic force microscopy10.1002/jps.10320 ↗
34. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products10.1016/j.ijpharm.2008.07.023 ↗
35. Crystallization of hydrocortisone acetate: influence of polymers10.1016/S0378-5173(00)00610-4 ↗
36. Formation and stabilisation of triclosan colloidal suspensions using supersaturated systems10.1016/S0378-5173(03)00299-0 ↗
37. Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS)10.1023/A:1015000503629 ↗
38. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer10.1021/mp100012s ↗
39. A screening study of surface stabilization during the production of drug nanocrystals10.1002/jps.21563 ↗
40. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions10.1016/j.ijpharm.2009.07.005 ↗
41. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement10.1080/03639040701741810 ↗
42. Understanding the structure and stability of paclitaxel nanocrystals10.1016/j.ijpharm.2010.02.013 ↗
43. Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications10.1016/j.ijpharm.2007.10.001 ↗
44. Production and characterization of Hesperetin nanosuspensions for dermal delivery10.1016/j.ijpharm.2008.12.030 ↗
45. A novel solid-in-oil nanosuspension for transdermal delivery of diclofenac sodium10.1007/s11095-007-9445-7 ↗
46. Oral delivery of diclofenac sodium using a novel solid-in-oil suspension10.1016/j.ijpharm.2006.02.003 ↗
47. Naproxen-eudragit® RS100 nanoparticles: preparation and physicochemical characterization10.1016/j.colsurfb.2010.11.014 ↗
48. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen10.1016/S0928-0987(02)00057-X ↗
49. Ocular tolerability of Eudragit RS100® and RL100® nanosuspensions as carriers for ophthalmic controlled drug delivery10.1002/jps.10227 ↗
50. Nanomedicines for ocular NSAIDs: safety on drug delivery10.1016/j.nano.2009.02.003 ↗
51. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs10.1016/j.ijpharm.2007.03.011 ↗
52. Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling10.1016/j.jconrel.2010.10.007 ↗
53. Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors10.1016/j.ijpharm.2009.03.029 ↗
54. Production and characterization of a budesonide nanosuspension for pulmonary administration10.1023/A:1014276917363 ↗
55. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers10.1177/0091270003261490 ↗
56. Hybrid nanocrystals: achieving concurrent therapeutic and bioimaging functionalities toward solid tumors10.1021/mp200154k ↗
57. Targeted cancer therapy with novel high drug-loading nanocrystals10.1002/jps.22112 ↗
58. In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity10.1016/j.ijpharm.2011.11.031 ↗
59. Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension10.1016/j.colsurfb.2010.10.029 ↗
60. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions10.1016/j.ijpharm.2007.12.016 ↗
61. Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice10.1016/j.colsurfb.2011.05.037 ↗
62. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer10.3109/03639041003695139 ↗
63. Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation10.1016/j.ijpharm.2011.09.041 ↗
64. The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis10.1080/10611860902718680 ↗
65. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood–brain barriers10.3109/10611861003733995 ↗
66. Drug delivery systems for intraperitoneal therapy10.1007/s11095-009-0031-z ↗
67. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model10.1007/s00280-002-0439-1 ↗
68. Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions10.1016/S0022-4804(03)00162-8 ↗
69. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics
70. de Bree · Anti-Cancer Drug · 2003 · 14 · 10310.1097/00001813-200302000-00003 ↗
71. Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer10.1006/gyno.2002.6665 ↗
72. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy10.1053/ctrv.2001.0232 ↗
73. Phase-I trial of intraperitoneal taxol – a gynecologic oncology group-study10.1200/JCO.1992.10.9.1485 ↗
74. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer10.1158/1078-0432.CCR-12-0261 ↗
75. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics10.2165/11598890-000000000-00000 ↗
76. Intraperitoneal therapy for peritoneal cancer10.2217/fon.10.100 ↗
77. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer
78. Intraperitoneal drug delivery of antineoplastics10.2165/00003495-200161080-00003 ↗
79. Evidence-based medicine in the treatment of peritoneal carcinomatosis: past, present, and future10.1002/jso.21323 ↗
80. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels10.1016/j.jconrel.2011.11.025 ↗
81. Intraperitoneal antineoplastic drug delivery: rationale and results10.1016/S1470-2045(03)01074-X ↗
82. Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration10.1002/jps.2600740902 ↗
83. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting10.1007/s00280-006-0256-z ↗
84. Theory and simulation of Ostwald ripening10.1103/PhysRevB.47.14110 ↗
85. Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening10.1016/j.ijpharm.2010.12.027 ↗
86. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening10.1021/la0523661 ↗
87. The role of interfacial rheological properties on Ostwald ripening in emulsions10.1016/j.cis.2003.10.005 ↗
88. Formation of emulsions
89. Optimization of formulation and process variable of nanosuspension: an industrial perspective10.1016/j.ijpharm.2010.09.041 ↗
90. Drying of crystalline drug nanosuspensions—The importance of surface hydrophobicity on dissolution behavior upon redispersion10.1016/j.ejps.2008.06.009 ↗
91. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors10.1016/j.jconrel.2011.12.001 ↗
92. Advantages of celecoxib nanosuspension formulation and transformation into tablets10.1016/j.ijpharm.2009.04.038 ↗
93. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam10.1016/j.ijpharm.2009.07.009 ↗
94. Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension10.1016/j.ijpharm.2009.09.030 ↗
95. Preparation of stable nitrendipine nanosuspensions using the precipitation – ultrasonication method for enhancement of dissolution and oral bioavailability10.1016/j.ejps.2010.04.006 ↗
96. Preparation of a chemically stable quercetin formulation using nanosuspension technology10.1016/j.ijpharm.2010.11.009 ↗